Analyst Ami Fadia of Needham maintained a Buy rating on Harmony Biosciences Holdings, retaining the price target of $41.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given his Buy rating due to a combination of factors including Harmony Biosciences Holdings’ strong financial performance and positive outlook. The company preannounced its third-quarter 2025 revenues for Wakix, which exceeded expectations by 7.6%, reaching $239 million compared to the consensus estimate of $220 million. This increase was driven by a significant rise in the average number of patients, marking the highest quarterly increase recorded.
Ami Fadia also noted the management’s decision to raise the full-year 2025 revenue guidance to a range of $845 to $865 million, which is approximately 2% higher than the previous guidance at the midpoint. This upward revision in guidance reflects confidence in the company’s growth trajectory. The anticipation of a positive market reaction to these announcements further supports the Buy rating, as investors are likely to respond favorably to the improved financial outlook.
According to TipRanks, Fadia is a 5-star analyst with an average return of 16.3% and a 51.40% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Biogen, and Harmony Biosciences Holdings.
In another report released on October 14, UBS also maintained a Buy rating on the stock with a $43.00 price target.